We use cookies to improve your experience on our site and to analyze traffic. By clicking "Accept", you consent to our use of cookies. Learn more.
Evidence
Publications & posters
Peer-reviewed publications and scientific posters from the Nova In Silico team and collaborators.
QSP platform of bispecific T-cell engager for multi-scale modeling: Blinatumomab study case
Hugo Alves, Paul Lemarre, Adèle L'Hostis, Ana Isis Toledo, Titouan Le Hong, Yishu Wang, Simon Arsène, Nasrin Afzal, T. Li, F.A., Singh, Jim Bosley, Craig Thalhauser
Learn more
A quantitative systems pharmacology model of heart failure with reduced ejection fraction to study impact of Guideline-Directed Medical Therapies on hospitalization and mortality outcomes
Emmanuel Peyronnet, François Riglet, Eulalie Courcelles, Alfonso Sartorius Carvajal, Sandrine Guilleminot, Richard Weaver, Sylvain Fouliard, Emmanuelle Bechet
Learn more
A mechanistic quantitative systems pharmacology model of atherosclerosis prospectively predicted LDL-C outcomes of the phase 3 CORALreef Lipids trial
Bertrand Cariou, Yishu Wang, Denis Angoulvant, Franck Boccara, Guillaume Mahé, Philippe Gabriel Steg, Emmanuelle Bechet
Learn more
From rich preclinical datasets to virtual patients: a QSP framework to support the development of an ADC in AML
Helio Wang, Anne Schneider, Georges-Alain Franzetti, Dylan Marchione, Najah Harouki Crochemore, Sylvain Fouliard, Simon Arsène, Vincent Madelain, Claire Couty
Learn more
A Mechanistic-Statistical QSP framework of Disease Progression and Clinical Outcomes in Prostate Cancer
Matthias Hanke, Théo Plissonneau, Adèle Hamelin, Philippe Pinton, Maria Deryabina, Lars-Erik Kyhl, Simon Bjerregaard, Jonas Eildal, Johan Kjellstroem, Cristhyne Leon
Learn more
Jinkō: A Modern Collaborative Integrated and Scalable QSP Modeling Platform
Louis Philippe, Samuel Laheux, Nicolas Duteil, Lara Brueziere, Eliott Tixier
Learn more
Prediction of inclisiran efficacy in patients with established atherosclerotic cardiovascular disease: the SIRIUS in-silico modelling of cardiovascular outcomes
Denis Angoulvant, Emmnanuel Peyronnet, Bertrand Cariou, Pierre Amarenco, Franck Boccara, Jean-Pierre Boissel, Alexandre Bastien, Eulalire Courcelles, Alizée Diatchenko, Anne Filipovics, Solène Granjeon-Noriot, Riad Kahoul, Guillaume Mahé, Lolita Portal, Solène Porte, Yishu Wang, Emmanuelle Bechet, Philippe Gabriel Steg
Learn more
Modeling of pemetrexed maintenance de-escalation strategies using digital twins-based in silico clinical trials in FLAURA2 regimen as front-line treatment of metastatic EGFR-mutated non-small cell lung cancer
M. Duruisseaux, A. Nativel, P. Masson, N. Girard, J. Cadranel, A. Swalduz, M. Giaj Levra, H. Giraud, N. Goyard, S. Musilli, N. Ratto, J. Bosley, E. Pham, A. L'Hostis, C. Monteiro
Learn more
A quantitative systems pharmacology (QSP) model to interrogate the underlying mechanisms of cholestatic pruritus (itch) in primary biliary cholangitis (PBC) and the impact of linerixibat treatment
Mario Giorgi, Matthias Hanke, Perrine Masson, Eulalie Courcelles, Janelle Lennie, Bishoy Hanna, Linda Casillas, Abdul-Azim Hassan, Sumanta Mukherjee, Mindy Magee, Megan McLaughlin, Jim Bosley, Simon Arsene, Hippolyte Darre, Anna Sher, Andreas E. Kremer, Brandon Swift
Learn more
In silico post-hoc simulations independently estimate the PFS outcomes of the Phase III Mariposa clinical trial
M. Duruisseaux, A. Nativel, P. Masson, N. Girard, J. Cadranel, A. Swalduz, E. Thibault-Greugny, G. Bouchard, D. Luo, Y. Su, J. Mehtal, P. Clemens, N. Haddish-Berhane, P. Mahadevia, J. Bosley, A. L'Hostis, N. Ratto, L. Etheve, C. Monteiro
Learn more
A Scalable, Traceable and Integrated Tool for Large QSP Models Calibration
Louis Philippe, Elea Thibault-Greugny, Tanguy Bourlier, Jean-Baptiste-Gourlet, Frederic Cogny
Learn more
Optimizing Clinical Trial Design Through In Silico Modeling, Virtual Populations and Mathematical Optimization
Riad Kahoul, Evgueni Jacob, Eliott Tixier, Jean-Baptiste Gourlet, Frederic Cogny
Learn more
Supporting ICH M15 Principles Through a Platform for Good Simulation Practices
Tanguy Bourlier, Arnaud Thomas Desessarts, Jean-Baptiste Gourlet, Frederic Cogny
Learn more
Enhancing Model Interoperability and Workflow Integration in Clinical Trial Simulations
Jean Ponchon, Elodie Prevot, Matthieu Coudron, Jeremy Villard, Nicolas Duteil, Riad Kahoul, Jean-Baptiste Gourlet, Frederic Cogny
Learn more
Automated Generation of Computational Models from Scientific Publications Using AI
Jean-Baptiste Gourlet, Elodie Prevot, Jeremy Villard, Frederic Cogny
Learn more
Enhancing Clinical Trial Simulations with Advanced Computational Techniques and Scalable Cloud Solutions
Guillaume Bouchard, Eliott Tixier, Jean-Baptiste Gourlet, Frederic Cogny - Nova In Silico, Lyon, France
Learn more
Coupling a QSP model with a simple statistical layer to predict asthma exacerbation rate reduction from allergen challenge results
Théo Galland, Cristhyne Leon, Caterina Sansone, Anne Vaslin Chessex, Christian Pasquali, Lorenz Lehr, Alexander Kulesza, Simon Arsène
Learn more
Towards a computational QSP platform to support ADC design in cancer
Théo Galland, Claire Couty, Brian Topp, Jim Bosley, Simon Arsène, Asher Hussain, Lara Bruzière
Learn more
Towards a QSP platform to support drug development in hematological cancers
P. Lemarre, A. Toledo, A. Schneider, M. Hanke, A. Kulesza, S. Arsène, B. Zhao, F. Alemdehy, L. Koopman, T. Li, N. Afzal, C. Thalhauser, J. Bosley, C. Couty
Learn more
Mathematical modeling can help to successfully translate preclinical findings in mice models of asthma into first-in-human trials
Cristhyne Leon, Théo Galland, Caterina Sansone, Anne Vaslin Chessex, Christian Pasquali, Lorenz Lehr, Alexander Kulesza, Simon Arsène
Learn more
A within-host dynamic model of B. pertussis to support vaccine development
Hippolyte Darré, Juan C. Vargas-Zambrano, Markus Rehberg, Britta Wagenhuber, Pascal Blanc, Alain Sabouraud, Denis Macina, Laurent Coudeville, Simon Arsène
Learn more
Dissecting Bcl-2 Sensitivity in AML: A QSP Model for Venetoclax-Azacitidine Therapy
Matthias Hanke, Satoshi Nakayama, Tomohisa Nakada, Claire Couty, Simon Arsène
Learn more
Combining a Quantitative Systemic Pharmacology (QSP) model of NSCLC with an existing KPD model of Gemcitabine: a first step towards a new paradigm in clinical trials simulation
Eléa Thibault-Greugny, Nicolas Ratto, Loic Ethève, Simon Arsène, Jim Bosley, Jean-Pierre Boissel, Nicholas Holford, Adèle L'Hostis, Claudio Monteiro
Learn more
Leveraging AI for improved reproducibility of mathematical disease models: insights from a retinitis pigmentosa case study
Elea Thibault Greugny, Nicolas Ratto, Loic Etheve, Jean-Baptiste Gourlet, Simon Arsène, Jim Bosley, Frederic Cogny, Claudio Monteiro
Learn more
Validation of an in-silico knowledge-based mechanistic model of atherosclerotic cardiovascular disease for the SIRIUS study
D. Angoulvant, P. Amarenco, A. Bastien, E. Bechet, F. Boccara, JP Boissel, B. Cariou, E. Courcelles, A. Diatchenko, S. Granjeon-Noriot, G. Mahé, E. Peyronnet, L. Portal, S. Porte, Y. Wang, P.G Steg
Learn more
Prospective validation of in silico clinical trials prediction using an EGFR-mutated NSCLC mechanistic computational disease model
M. Duruisseaux, P. Masson, A. Nativel, N. Girard, J. Cadranel, A. Swalduz, M. Coudron, G. Bouchard, R. Kahoul, E. Jacob, J. Bosley, JL. Palgen, A. L'Hostis, C. Monteiro
Learn moreComparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma
by Hippolyte Darré, Perrine Masson, Arnaud Nativel, Laura Villain, Diane Lefaudeux, Claire Couty, Bastien Martin, Evgueni Jacob, Michaël Duruisseaux, Jean-Louis Palgen, Claudio Monteiro and Adèle L’Hostis
Learn moreA quantitative systems pharmacology workflow toward optimal design and biomarker stratification of atopic dermatitis clinical trials
Natacha Go, Simon Arsène, Igor Faddeenkov, Théo Galland, Shiny Martis B., Diane Lefaudeux, Yishu Wang, Loic Etheve, Evgueni Jacob, Claudio Monteiro, Jim Bosley, Caterina Sansone, Christian Pasquali, Lorenz Lehr, Alexander Kulesza,
Learn more
Predicting the efficacy of Inclisiran on cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease: primary results of the in silico SIRIUS trial
D. Angoulvant, P.Amarenco, A.Bastien, E. Bechet, F. Boccara, JP. Boissel, B. Cariou, E. Courcelles, A. Diatchenko, A. Filipovics, S. Granjeon-Noriot, R. Kahoul, G. Mahé, E. Peyronnet, L. Portal, S. Porte, Y. Wang, P.G. Steg
Learn more
In Silico Clinical Trials Using Mechanistic Knowledge-Based Model, an Innovative Approach to Accelerate Data Generation and Support Health Technology Assessment
E. Pham, S. Porte, E. Courcelles, E. Peyronnet, Y. Wang, A. Diatchenko, G.Gomez, P. Amarenco, D. Angoulvant, F. Boccara, B. Cariou, G. Mahé, N. Marquet, A. Bastien, L. Portal, JP. Boissel, E. Bechet, S. Granjeon-Noriot, P.G. Steg
Learn more
A multiscale model of atherosclerotic cardiovascular disease to predict lipid lowering therapies effect on clinical events
S. Porte, E. Courcelles, E. Peyronnet, Y. Wang, P. Amarenco, D. Angoulvant, F. Boccara, B. Cariou, G. Mahé, P.G. Steg, A. Bastien, L. Portal, L. Bruziere, E. Bechet, S. Granjeon-Noriot
Learn more
Empirical methods for the validation of time-to-event mathematical models taking into account uncertainty and variability: application to EGFR + lung adenocarcinoma
Evgueni Jacob, Angélique Perrillat-Mercerot, Jean-Louis Palgen, Adèle L’Hostis, Nicoletta Ceres, Jean-Pierre Boissel, Jim Bosley, Claudio Monteiro, Riad Kahoul
Learn more
Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma
Adèle L’Hostis, Jean-Louis Palgen, Angélique Perrillat-Mercerot, Emmanuel Peyronnet, Evgueni Jacob, James Bosley, Michaël Duruisseaux, Raphaël Toueg, Lucile Lefèvre, Riad Kahoul, Nicoletta Ceres, Claudio Monteiro
Learn more
Design of a knowledge-based mechanistic model of atherosclerotic cardiovascular disease for in silico trials
D. Angoulvant1, P. Amarenco2, A. Bastien3, E. Bechet4, F. Boccara5, JP. Boissel4, B. Cariou6, E. Courcelles4, S. Granjeon-Noriot4, G. Mahé7, E. Peyronnet4, L. Portal3, S. Porte4, Y. Wang4, P.G. Steg8
Learn more
Exploring the impact of assuming spherical tumors on the modeled clinical outcome through the analysis of tumor measurements and in silico simulations
J. Kleine-Schultjann1, G. Gómez1, A. L'Hostis1, J-L. Palgen1, C. Monteiro1, P. Masson1
Learn more
The combination of statistical methods to compare observed and simulated data allowed to assess effectively the validity of mathematical model predictions in a context of a EGFR+ Lung Adenocarcinoma
Evgueni Jacob1, Laura Villain1, Nicoletta Ceres1, Jean-Louis Palgen1, Adèle L'Hostis1, Claudio Monteiro1, Riad Kahoul1
Learn more
Simulations of tumor heterogeneity impact on treatment response using a mechanistic model of EGFR-mutant lung adenocarcinoma
P Masson1, C Couty1, A Nativel1, E Jacob1, R Toueg2, M Duruisseaux3, A L’Hostis1, JL Palgen1, C Monteiro1
Learn more
Comparison of the effect of two EGFR-TKI in patients with EGFR-mutant lung adenocarcinoma using in silico clinical trials
H. Darré1, B. Martin1, F. Hammami1, A. Nativel1, D. Lefaudeux1, R. Toueg2, M. Duruisseaux3, J-L. Palgen1, P. Masson1, A. L’Hostis1, N. Ceres1, C. Monteiro1
Learn more
Effectiveness of high dose versus standard dose influenza vaccines in older adults : insights from a multi-strain modeling approach
Urdy, S.; Ratto, N.; Hanke, M.; Toledo, A. I.; Peyronnet, E.; Jacob, E.; Thommes, E.; Chaves, S.; Coudeville, L.; Boissel, J. P.; Bruezière, L. and Courcelles, E.
Learn more
Characterization of optimal clinical trial design and best responders characteristics using mechanistic modeling Application to Chronic HBV
Solène Granjeon-Noriot, Anne Schneider, Solène Porte, Emmanuel Peyronnet, Pietro Scalfaro, Emmanuel Pham, Lara Bruezière
Learn morePredictive validity in drug discovery: what it is, why it matters and how to improve it
Jack W. Scannell, James Bosley, John A.Hickman, Gerard R. Dawson, Hubert Truebel, Guilherme S. Ferreira, Duncan Richards and J.Mark Treherne
Learn more
In silico clinical trial shows the efficacy of the inhibition of reactive oxygen species production in ST elevated myocardial infarction
E. Peyronnet, E. Courcelles, B. Martin, B. Le Grand, D. Du Verle, E. Jacob, N. Ceres, E. Bechet, L. Etheve, A. L’Hostis,C. Thompson, A. Boucard, F. Marin, J.P. Boissel
Learn more
Modeling tumor heterogeneity evolution in lung adenocarcinoma
Claire Couty, Perrine Masson, Arnaud Nativel, Firas Hammami, Angélique Perrillat-Mercerot, Matthieu Coudron, Evgueni Jacob, Lucile Lefèvre, Raphaël Toueg, Aurélie Swalduz, Jean-Louis Palgen, Claudio Monteiro, Adèle L'Hostis
Learn more
Integration of heterogeneous biological data in multiscale mechanistic model calibration
Jean-Louis Palgen, Angélique Perrillat-Mercerot, Nicoletta Ceres, Emmanuel Peyronnet, Matthieu Coudron, Jim Bosley, Adèle L'Hostis, Claudio Monteiro
Learn more
Modelling variability of chronic HBV patient response to treatments
Anne S, Solène P, Solène SG
Learn more
Building a cloud simulation system for reproducible and multi-level cached in-silico trials
Eliott Tixier, Matthieu Coudron, Yves Parès
Learn more
A virtual population approach to support atopic dermatitis clinical trial design and biomarker identification
Igor Faddeenkov, Simon Arsène, Alexander Kulesza
Learn more
Viral kinetic modeling and simulation of the impact of non-pharmaceutical COVID-19 interventions in different countries: model-informed respiratory disease trial design
Igor Faddeenkov, Simon Arsène, Alexander Kulesza
Learn more
Integration of Heterogeneous Biological Data in Multiscale Mechanistic Model Calibration: Application to Lung Adenocarcinoma
Jean‑Louis Palgen, Angélique, Perrillat‑Mercerot, Nicoletta Ceres, Emmanuel Peyronnet, Matthieu Coudron, Eliott Tixier, Ben M. W. Illigens, Jim Bosley, Adèle L’Hostis, Claudio Monteiro
Learn more
A mechanistic skin immunology model for the support of atopic dermatitis clinical trial design and biomarker programs
Théo Galland, Igor Faddeenkov, Simon Arsène, Alexander Kulesza
Learn more
In silico Modelling suggests reduced occurrence of End-Stage Kidney Disease after 20yrs treatment with rhPTH(1-84) in patients with hypoparathyroidism not adequately controlled with Standard of Care
E. Bechet, N Schmidely
Learn more
Viral kinetic modeling and clinical trial simulation predicts disruption of respiratory disease trials by non-pharmaceutical COVID-19 interventions
Simon Arsène, Alexander Kulesza, Igor Faddeenkov, Théo Galland, Cristhyne Leon
Learn more
A PBPK and immunogenicity model integrated into two disease models
Simon Arsène, Alexander Kulesza, Igor Faddeenkov, Théo Galland, Cristhyne Leon
Learn more
Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions
Simon Arsène , Claire Couty , Igor Faddeenkov , Natacha Go , Solène Granjeon-Noriot , Daniel Smit , Riad Kahoul , Ben Illigens , Jean-Pierre Boissel , Aude Chevalier , Lorenz Lehr , Christian Pasquali
Learn more
Multiscale EGFR mutated NSCLC tumor heterogeneity knowledge-based model predicts tumor growth under Gefitinib: an avenue to in silico clinical trial
M. Duruisseaux1, J-L. Palgen, A. Perrillat-Mercerot, N. Ceres, E. Peyronnet, E. Jacob, R. Kahoul, M. Coudron, M. Poiré, L. Lefevre, R. Toueg, J. Bosley, A. L’Hostis, C. Monteiro
Learn more
Model integration in computational Biology: the Role of reproducibility, credibility and utility
Jonathan Karr, Rahuman S. Malik-Sheriff, James Osborne, Gilberto Gonzalez-Parra, Eric Forgoston, Ruth Bowness, Yaling Liu, Robin Thompson, Winston Garira, Jacob Barhak, John Rice, Marcella Torres, Hana M. Dobrovolny, Tingting Tang, William Waites, James A. Glazier, James R. Faeder and Alexander Kulesza
Learn more
Model based meta-analysis of the effect of non-specific immunomodulation with OM-85 for recurrent viral respiratory tract infections and wheezing: a multi-scale mechanistic approach
Simon Arsène, Alexander Kulesza
Learn moreApplication of a mechanistic model to forecast RTI prophylaxis trial feasibility in the post-COVID era
Igor Faddeenkov, Simon Arsène, Alexander Kulesza
Learn more
Mechanistic modeling to optimize phase 2b clinical trial design of a new combination therapy for chronic HBV
Solène Granjeon-Noriot1, Anne Schneider1, Emmanuel Peyronnet1, Eulalie Courcelles1, Claire Couty1, Bastien Martin1, Simon Arsène1, Hippolyte Darré1, Evgueni Jacob1, Riad Kahoul1, Hugo Girma2, Marion Odoul2, Isabelle Martin2, Laurène Meyniel-Schicklin2, Dr. Pietro Scalfaro2, Dr. Ben Illigens1,3 and Lara Bruezière1.
Learn more
Application of knowledge-based mechanistic modeling to optimize phase III clinical trials of targeted therapy
A. L’Hostis1, J-L. Palgen1, N. Ceres1, A. Perrillat-Mercerot1, E. Jacob1, R. Kahoul1, M. Coudron1, G. Bouchard1, B.M.W. Illigens1,2, M. Hommel1, J.P. Boissel1, J. Bosley1, C. Monteiro1
Learn more
Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample
Boissel JP, Pérol D, Décousus H, Klingmann I, Hommel M
Learn moreMultiscale NSCLC tumor growth knowledge based model reproduces tumor non progression under Gefitinib
Adèle L'Hostis, J.-L. Palgen, N. Ceres, E. Peyronnet, A. Perrillat-Mercerot, A. Schneider, M. Margreiter, E. Jacob
Learn moreUse of a multiscale NSCLC tumor heterogeneity model to predict tumor growth under Gefitinib
Adèle L'Hostis, J.-L. Palgen, N. Ceres, E. Peyronnet, A. Perrillat-Mercerot, A. Schneider, M. Margreiter, E. Jacob
Learn more
Mechanistic model based meta-analysis for paediatric respiratory tract infection prophylaxis trial design
Alexander Kulesza, Simon Arsène, Jean-Pierre Boissel
Learn more
In silico clinical trial simulation shows amelioration of ischemia-reperfusion injury in ST-elevation myocardial infarction via inhibition of reactive oxygen species production
B. Martin, E. Courcelles, A. L’Hostis, L. Etheve, E. Bechet, N. Ceres, E. Jacob, E. Peyronnet, B. M.W. Illigens, M. Hommel, J.P. Boissel
Learn more
Possible contexts of use for in silico trials methodologies: a consensus- based review
Marco Viceconti, Luca Emili, Payman Afshari, Eulalie Courcelles, Cristina Curreli, Nele Famaey, Liesbet Geris, Marc Horner, Maria Cristina Jori, Alexander Kulesza, Axel Loewe, Michael Neidlin, Markus Reiterer, Cecile F. Rousseau, Giulia Russo, Simon J. Sonntag, Emmanuelle M. Voisin, and Francesco Pappalardo
Learn more
Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: building model credibility
Flora T. Musuamba, Ine Skottheim Rusten, Raphaëlle Lesage, Giulia Russo, Roberta Bursi, Luca Emili, Gaby Wangorsch, Efthymios Manolis, Kristin E. Karlsson, Alexander Kulesza, Eulalie Courcelles, Jean-Pierre Boissel, Cécile F. Rousseau, Emmanuelle M. Voisin, Rossana Alessandrello, Nuno Curado, Enrico Dall’ara, Blanca Rodriguez, Francesco Pappalardo, Liesbet Geris
Learn more
Solving the evidence interpretability crisis in health technology assessment: a role for mechanistic models?
Eulalie Courcelles, Jean-Pierre Boissel, Jacques Massol, Ingrid Klingmann, Riad Kahoul, Marc Hommel, Emmanuel Pham and Alexander Kulesza
Learn more
In silico clinical trial shows the efficacy of the inhibition of reactive oxygen species production in ST elevated myocardial infarction
Emmanuel Peyronnet; Eulalie Courcelles; Bastien Martin
Learn more
Verifying and Validating Quantitative Systems Pharmacology and In Silico Models in Drug Development: Current Needs, Gaps, and Challenges.
Flora T. Musuamba Roberta Bursi Efthymios Manolis Kristin Karlsson Alexander Kulesza Eulalie Courcelles Jean‐Pierre Boissel Raphaëlle Lesage Cécile Crozatier Emmanuelle M. Voisin Cécile F. Rousseau Thierry Marchal Rossana Alessandrello and Liesbet Geris.
Learn more
An in silico disease model for the development of FXR agonist EYP001 as a therapy for HBV infection
Claudio Monteiro, Lara Bruezière, Samuel Laheux, Marc Hommel, Pauline Radreau, Elise Roy, Raphaël Darteil, Patrice André, Jean-Pierre Boissel, Jacky Vonderscher and Pietro Scalfaro.
Learn more